AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all previous versions and listings of claims in this application:

1-23. (Cancelled)

24. (Currently Amended) The suspension of ~~claim 23~~ claim 32, wherein the amount of ~~peptide or peptidomimetic~~ Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2·trifluoracetate ranges from about 0.1 to 5 mg per kg body weight of a mammal or human to which the suspension is to be administered.

25-31. (Cancelled)

32. (Currently Amended) A fluid, milky microcrystalline aqueous suspension comprising Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2·trifluoroacetate and an isotonic agent.

33. (Previously Presented) The suspension of claim 32, which provides, when administered to a subject, a sustained release of peptide *in vivo*.

34. (Previously Presented) The suspension of claim 33, wherein the sustained release is over a period of two weeks.

35. (Previously Presented) The suspension of claim 32, wherein Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2·trifluoroacetate is suspended in an aqueous medium at a concentration of equal to or greater than 25 mg/mL.

36. (Cancelled)

37. (Currently Amended) The suspension of ~~claim 36~~ claim 32, wherein the isotonic agent is mannitol.

38. (Previously Presented) The suspension of claim 32, further comprising a pharmaceutically acceptable excipient.

39. (Previously Presented) The suspension of claim 32, wherein microcrystals are in the form of needles having a particle size of between 1 and 150 μm.

40. (Previously Presented) A method of preparing the suspension of claim 32 comprising, associating Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2 with trifluoroacetate counter-ion in an amount and at a molar ratio that are sufficient to provide a fluid, milky microcrystalline aqueous suspension without formation of a gel.

41. (Previously Presented) A method of preparing a lyophilized composition comprising Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2·trifluoroacetate comprising, lyophilizing the suspension of claim 32.

42. (Previously Presented) A lyophilized composition comprising a dried suspension obtained by lyophilizing the suspension of claim 32.

43. (Previously Presented) A method of preparing a microcrystalline aqueous suspension of Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2·trifluoroacetate comprising, adding water or buffer with mixing to the lyophilized composition of claim 42.

44. (Previously Presented) A method of preparing the suspension of claim 32 comprising, associating Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2 with trifluoroacetate counter-ion in an amount and at a molar ratio that are sufficient to provide a fluid, milky microcrystalline aqueous suspension without formation of a gel; lyophilizing to form a lyophilized composition; and adding water or buffer with mixing.

45-59. (Cancelled)

60. (Currently Amended) A method of preparing a sustained release formulation of ~~a peptide or peptidomimetic, which comprises~~ Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2·trifluoroacetate comprising, associating ~~the peptide or peptidomimetic~~ Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2 with the trifluoroacetate counter-ion in an amount and at a molar ratio that are sufficient to provide the fluid, milky microcrystalline aqueous suspension of ~~claim 12~~ claim 32, such that, when administered to a subject, the peptide is released *in vivo* over a period of at least two weeks.

61-62. (Cancelled)

63. (Currently Amended) The method of ~~claim 62~~ claim 60, wherein the aqueous suspension is injected parenterally into a mammal or human subject to obtain a sustained release of ~~the peptide or peptidomimetic over~~ Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2·trifluoroacetate for at least one month to about 45 days.

64. (Currently Amended) The method of ~~claim 62~~ claim 60, wherein the amount of ~~peptide or peptidomimetic~~ Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH_2·trifluoroacetate in the suspension to be injected ranges from about 0.1 to 5 mg per kg body weight of the mammal or human subject.

65-67. (Cancelled)